Lan Keng-Hsueh, Lu Chien-Hsing, Yu Dihua
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Ann N Y Acad Sci. 2005 Nov;1059:70-5. doi: 10.1196/annals.1339.026.
Trastuzumab (Herceptin) is an excellent model of rationally designed targeted cancer treatment. However, less than 35% of patients with ErbB2-positive breast tumors respond to trastuzumab as a single agent, and 2-5% of trastuzumab-treated patients suffer from severe side effects, including cardiac dysfunction. Recent progress in understanding the mechanisms of trastuzumab antitumor function and cellular defects leading to trastuzumab resistance is summarized. Also explored is the potential of combination therapies for reversing trastuzumab resistance.
曲妥珠单抗（赫赛汀）是合理设计的靶向癌症治疗的一个优秀范例。然而，在ErbB2阳性乳腺肿瘤患者中，不到35%的患者对单一使用曲妥珠单抗有反应，并且2%-5%接受曲妥珠单抗治疗的患者会出现严重副作用，包括心脏功能障碍。本文总结了在理解曲妥珠单抗抗肿瘤功能机制以及导致曲妥珠单抗耐药的细胞缺陷方面的最新进展。同时也探讨了联合治疗逆转曲妥珠单抗耐药的潜力。
